Comera Life Sciences Holdings, Inc. (CMRA)
OTCMKTS · Delayed Price · Currency is USD
0.0002
+0.0001 (100.00%)
At close: Dec 23, 2024

CMRA Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2022 FY 2021 FY 2020
Period Ending
Sep '23 Dec '22 Dec '21 Dec '20
Revenue
10.630.320.44
Revenue Growth (YoY)
81.79%97.95%-27.79%-
Cost of Revenue
0.260.210.160.1
Gross Profit
0.740.420.160.34
Selling, General & Admin
7.129.324.11.2
Research & Development
1.271.571.61.26
Operating Expenses
8.3810.895.692.47
Operating Income
-7.65-10.47-5.54-2.13
Interest Expense
-0.03-0.02--
Other Non Operating Income (Expenses)
0.16-5.59--0.13
EBT Excluding Unusual Items
-7.51-16.08-5.54-2.26
Other Unusual Items
-1.5-2.090.08-
Pretax Income
-9.01-18-5.45-2.13
Net Income
-9.01-18-5.45-2.13
Preferred Dividends & Other Adjustments
0.340.37--
Net Income to Common
-9.35-18.38-5.45-2.13
Shares Outstanding (Basic)
2010311
Shares Outstanding (Diluted)
2010311
Shares Change (YoY)
212.24%246.97%-72.74%-
EPS (Basic)
-0.48-1.76-1.81-0.19
EPS (Diluted)
-0.48-1.76-1.81-0.19
Free Cash Flow
-6.76-9.8-3.9-1.82
Free Cash Flow Per Share
-0.35-0.94-1.29-0.16
Gross Margin
73.52%66.77%49.66%76.43%
Operating Margin
-764.38%-1653.76%-1730.79%-480.34%
Profit Margin
-934.95%-2902.84%-1704.58%-479.88%
Free Cash Flow Margin
-675.24%-1547.99%-1219.38%-410.11%
EBITDA
-7.55-10.38-5.45-2.04
D&A For EBITDA
0.10.090.090.09
EBIT
-7.65-10.47-5.54-2.13
Source: S&P Capital IQ. Standard template. Financial Sources.